GT Biopharma, Inc. 8-K

What Happened GT Biopharma, Inc. (GTBP) reported on Form 8-K that its Board approved an amendment to the company's Amended and Restated Bylaws on June 8, 2026. The amendment lowers the number of shares required to be present in person or by proxy to establish a quorum at a stockholder meeting from a majority of outstanding voting shares to not less than one-third (1/3) of outstanding voting shares.

Key Details

• Amendment approved by the Board on June 8, 2026; effective the same date.
• Quorum requirement changed from a majority (>50%) to one-third (1/3) of outstanding shares entitled to vote.
• Board cited increasing instances of brokerage firms declining discretionary or proportionate voting of street-name shares as the reason for the change.
• The full text of the amendment is included as Exhibit 3.1 to the filing.

Why It Matters The bylaw change is intended to make it easier for GT Biopharma to obtain a quorum and hold shareholder meetings when called. For investors, this increases the likelihood that meetings will proceed as scheduled even if many holders (or brokered street-name shares) do not cast votes, which can affect timing and outcomes of votes on corporate matters.